Epigenetic Nucleosomes in Plasma for Pulmonary Nodule Differentiation
ConditionLung Nodule
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20+
SponsorNational Taiwan University Hospital
About this trial
Investigators aim to evaluate the diagnostic accuracy of the Nu.Q blood test for lung cancer in the Taiwanese population and compare its diagnostic performance with low-dose computed tomography (LDCT) or computed tomography (CT). Additionally, investigators will investigate the potential role of Nu.Q in lung cancer prevention and its impact on survival outcomes.
Study Method:
Investigators plan to collect 20 mL of blood samples from individuals undergoing chest LDCT/CT, isolate plasma for Nu.Q™ analysis, and compare the results with corresponding lung cancer pathology findings. The estimated sample size is 500 participants.
Eligibility criteria
Qualifiers
Aged 20 or older
Underwent a low-dose chest CT scan or a standard chest CT scan, showing lung nodules ≥ 6mm
Individuals understand the content of the consent form and are willing to participate in this study.
The lung nodule is assessed by a physician as high-risk, requiring thoracic surgery or biopsy for diagnosis
Disqualifiers
Pregnant women
Individuals without capacity for consent, unable to understand the content of the consent form, or unwilling to participate in this study
Assessed by a physician as unsuitable for thoracic surgery or biopsy for diagnosis
Trial design
Treatments tested in this trial
- blood draw
Treatment groups
No treatment groups listed
Sponsors and collaborators
National Taiwan University Hospital
Lead sponsor
Volition Diagnostics UK Ltd
Collaborator
Source ClinicalTrials.gov